{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:20:01Z","timestamp":1778545201774,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,7]]},"DOI":"10.7759\/cureus.53784","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T20:55:01Z","timestamp":1707339301000},"source":"Crossref","is-referenced-by-count":1,"title":["The Safety and Efficacy of the Early Use of Sacubitril\/Valsartan After Acute Myocardial Infarction: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Abdullah","family":"-","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuauhtemoc Jeffrey","family":"Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghazala S","family":"Virk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Favour C","family":"Mekowulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandipkumar S","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saima","family":"Batool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Usama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-39226-6.00018-7","article-title":"Acute myocardial infarction","author":"Wu JC","year":"2019","unstructured":"Wu JC. Acute myocardial infarction. Essential Echocardiography. Solomon SD, Wu JC, Gillam LD (ed): Elsevier, Amsterdam, Netherlands; 2019. 2:195-99. 10.1016\/B978-0-323-39226-6.00018-7"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5603\/KP.2018.0203","article-title":"Fourth universal definition of myocardial infarction (2018) (Article in Polish)","volume":"76","author":"Thygesen K","year":"2018","unstructured":"Thygesen K, Alpert JS, Jaffe AS, et al.. Fourth universal definition of myocardial infarction (2018) (Article in Polish). Kardiol Pol. 2018, 76:1383-415. 10.5603\/KP.2018.0203","journal-title":"Kardiol Pol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyq165","article-title":"World Health Organization definition of myocardial infarction: 2008-09 revision","volume":"40","author":"Mendis S","year":"2011","unstructured":"Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, M\u00e4h\u00f6nen M, Ngu Blackett K, Lisheng L. World Health Organization definition of myocardial infarction: 2008-09 revision. Int J Epidemiol. 2011, 40:139-46. 10.1093\/ije\/dyq165","journal-title":"Int J Epidemiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2014.01.166","article-title":"Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction)","volume":"7","author":"Guerchicoff A","year":"2014","unstructured":"Guerchicoff A, Brener SJ, Maehara A, et al.. Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction). JACC Cardiovasc Interv. 2014, 7:733-40. 10.1016\/j.jcin.2014.01.166","journal-title":"JACC Cardiovasc Interv"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2021.0320","article-title":"Global Awareness of Myocardial Infarction Symptoms in General Population","volume":"51","author":"Kim SJ","year":"2021","unstructured":"Kim SJ. Global Awareness of Myocardial Infarction Symptoms in General Population. Korean Circ J. 2021, 51:997-1000. 10.4070\/kcj.2021.0320","journal-title":"Korean Circ J"},{"key":"ref6","article-title":"Percutaneous Coronary Intervention","author":"Ahmad M","year":"2023","unstructured":"Ahmad M, Mehta P, Reddivari AKR, Mungee S. Percutaneous Coronary Intervention. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12544","article-title":"Sacubitril\/valsartan in heart failure and end-stage renal insufficiency","volume":"6","author":"Heyse A","year":"2019","unstructured":"Heyse A, Manhaeghe L, Mahieu E, Vanfraechem C, Van Durme F. Sacubitril\/valsartan in heart failure and end-stage renal insufficiency. ESC Heart Fail. 2019, 6:1331-3. 10.1002\/ehf2.12544","journal-title":"ESC Heart Fail"},{"key":"ref8","article-title":"Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI)","volume":"8","author":"Liu Y","year":"2015","unstructured":"Liu Y, Liu H, Hao Z, et al.. Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI). Int J Clin Exp Med. 2015, 8:11360-9.","journal-title":"Int J Clin Exp Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-018-9757-1","article-title":"Practical guidance on the use of sacubitril\/valsartan for heart failure","volume":"24","author":"Sauer AJ","year":"2019","unstructured":"Sauer AJ, Cole R, Jensen BC, Pal J, Sharma N, Yehya A, Vader J. Practical guidance on the use of sacubitril\/valsartan for heart failure. Heart Fail Rev. 2019, 24:167-76. 10.1007\/s10741-018-9757-1","journal-title":"Heart Fail Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2019.10.006","article-title":"Temporal trends in the prevalence and outcomes of geriatric patients with acute myocardial infarction in Japan-a report from the Miyagi AMI Registry Study","volume":"75","author":"Sato K","year":"2020","unstructured":"Sato K, Takahashi J, Hao K, et al.. Temporal trends in the prevalence and outcomes of geriatric patients with acute myocardial infarction in Japan-a report from the Miyagi AMI Registry Study. J Cardiol. 2020, 75:465-72. 10.1016\/j.jjcc.2019.10.006","journal-title":"J Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon SD","year":"2020","unstructured":"Solomon SD, Vaduganathan M, L Claggett B, et al.. Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020, 141:352-61. 10.1161\/CIRCULATIONAHA.119.044586","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.10.011","article-title":"Management of acute left ventricular dysfunction after primary percutaneous coronary intervention for ST elevation acute myocardial infarction","volume":"160","author":"Saia F","year":"2010","unstructured":"Saia F, Grigioni F, Marzocchi A, Branzi A. Management of acute left ventricular dysfunction after primary percutaneous coronary intervention for ST elevation acute myocardial infarction. Am Heart J. 2010, 160:S16-21. 10.1016\/j.ahj.2010.10.011","journal-title":"Am Heart J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1234","article-title":"Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis","volume":"20","author":"Komajda M","year":"2018","unstructured":"Komajda M, B\u00f6hm M, Borer JS, Ford I, Tavazzi L, Pannaux M, Swedberg K. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail. 2018, 20:1315-22. 10.1002\/ejhf.1234","journal-title":"Eur J Heart Fail"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes R","year":"2018","unstructured":"Haynes R, Judge PK, Staplin N, et al.. Effects of sacubitril\/valsartan versus irbesartan in patients with chronic kidney disease. Circulation. 2018, 138:1505-14. 10.1161\/CIRCULATIONAHA.118.034818","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044491","article-title":"Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF","volume":"141","author":"McMurray JJ","year":"2020","unstructured":"McMurray JJ, Jackson AM, Lam CS, et al.. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation. 2020, 141:338-51. 10.1161\/CIRCULATIONAHA.119.044491","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.01.018","article-title":"B-type natriuretic peptide during treatment with sacubitril\/valsartan: the PARADIGM-HF trial","volume":"73","author":"Myhre PL","year":"2019","unstructured":"Myhre PL, Vaduganathan M, Claggett B, et al.. B-type natriuretic peptide during treatment with sacubitril\/valsartan: the PARADIGM-HF trial. J Am Coll Cardiol. 2019, 73:1264-72. 10.1016\/j.jacc.2019.01.018","journal-title":"J Am Coll Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic JP","year":"2017","unstructured":"Seferovic JP, Claggett B, Seidelmann SB, et al.. Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017, 5:333-40. 10.1016\/S2213-8587(17)30087-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","unstructured":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987, 316.1429-35. 10.1056\/NEJM198706043162301","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92693-N","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","unstructured":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993, 342:821-8. 10.1016\/0140-6736(93)92693-N","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer MA","year":"1992","unstructured":"Pfeffer MA, Braunwald E, Moy\u00e9 LA, et al.. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992, 327:669-77. 10.1056\/NEJM199209033271001","journal-title":"N Engl J Med"},{"key":"ref21","article-title":"Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)","volume":"1","year":"1986","unstructured":"Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet. 1986, 1.397-402.","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.98.24.2649","article-title":"Ten years of benefit from a one-hour intervention","volume":"98","author":"Califf RM","year":"1998","unstructured":"Califf RM. Ten years of benefit from a one-hour intervention. Circulation. 1998, 98:2649-51. 10.1161\/01.cir.98.24.2649","journal-title":"Circulation"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer M","year":"2015","unstructured":"Packer M, McMurray JJ, Desai AS, et al.. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015, 131:54-61. 10.1161\/CIRCULATIONAHA.114.013748","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon SD","year":"2019","unstructured":"Solomon SD, McMurray JJ, Anand IS, et al.. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019, 381:1609-20. 10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"key":"ref25","article-title":"In brief: sacubitril\/valsartan (Entresto) expanded indication","volume":"63","year":"2021","unstructured":"In brief. sacubitril\/valsartan (Entresto) expanded indication. Med Lett Drugs Ther. 2021, 63:65.","journal-title":"Med Lett Drugs Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.794","article-title":"Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril\/valsartan)","volume":"9","author":"Eadie AL","year":"2021","unstructured":"Eadie AL, Brunt KR, Herder M. Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril\/valsartan). Pharmacol Res Perspect. 2021, 9:e00794. 10.1002\/prp2.794","journal-title":"Pharmacol Res Perspect"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/7840852","article-title":"Effects and safety of sacubitril\/valsartan for patients with myocardial infarction: a systematic review and meta-analysis","volume":"2022","author":"Liu L","year":"2022","unstructured":"Liu L, Ding X, Han Y, Lv J. Effects and safety of sacubitril\/valsartan for patients with myocardial infarction: a systematic review and meta-analysis. J Healthc Eng. 2022, 2022:7840852. 10.1155\/2022\/7840852","journal-title":"J Healthc Eng"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13677","article-title":"The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis","volume":"8","author":"Xiong B","year":"2021","unstructured":"Xiong B, Nie D, Qian J, et al.. The benefits of sacubitril-valsartan in patients with acute myocardial infarction: a systematic review and meta-analysis. ESC Heart Fail. 2021, 8:4852-62. 10.1002\/ehf2.13677","journal-title":"ESC Heart Fail"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23717","article-title":"Efficacy and safety of early initiation of sacubitril\/valsartan in patients after acute myocardial infarction: A meta-analysis","volume":"44","author":"Zhao J","year":"2021","unstructured":"Zhao J, Zeng Y, Shen X. Efficacy and safety of early initiation of sacubitril\/valsartan in patients after acute myocardial infarction: A meta-analysis. Clin Cardiol. 2021, 44:1354-9. 10.1002\/clc.23717","journal-title":"Clin Cardiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2020.10.012","article-title":"The effect of sacubitril-valsartan in heart failure patients with mid-range and preserved ejection fraction: a meta-analysis","volume":"30","author":"Nie D","year":"2021","unstructured":"Nie D, Xiong B, Qian J, Rong S, Yao Y, Huang J. The effect of sacubitril-valsartan in heart failure patients with mid-range and preserved ejection fraction: a meta-analysis. Heart Lung Circ. 2021, 30:683-91. 10.1016\/j.hlc.2020.10.012","journal-title":"Heart Lung Circ"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000643","article-title":"Titration and tolerability of sacubitril\/valsartan for patients with heart failure in clinical practice","volume":"73","author":"Du AX","year":"2019","unstructured":"Du AX, Westerhout CM, McAlister FA, et al.. Titration and tolerability of sacubitril\/valsartan for patients with heart failure in clinical practice. J Cardiovasc Pharmacol. 2019, 73:149-54. 10.1097\/FJC.0000000000000643","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000096609.73772.C5","article-title":"Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system","volume":"109","author":"L\u00e9vy BI","year":"2004","unstructured":"L\u00e9vy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation. 2004, 109:8-13. 10.1161\/01.CIR.0000096609.73772.C5","journal-title":"Circulation"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition","volume":"133","author":"Hubers SA","year":"2016","unstructured":"Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 2016, 133:1115-24. 10.1161\/CIRCULATIONAHA.115.018622","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.06.020","article-title":"Sacubitril\/valsartan: neprilysin inhibition 5 years after PARADIGM-HF","volume":"8","author":"Docherty KF","year":"2020","unstructured":"Docherty KF, Vaduganathan M, Solomon SD, McMurray JJ. Sacubitril\/valsartan: neprilysin inhibition 5 years after PARADIGM-HF. JACC Heart Fail. 2020, 8:800-10. 10.1016\/j.jchf.2020.06.020","journal-title":"JACC Heart Fail"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz058","article-title":"Chronic kidney disease, heart failure and neprilysin inhibition","volume":"35","author":"Haynes R","year":"2020","unstructured":"Haynes R, Zhu D, Judge PK, Herrington WG, Kalra PA, Baigent C. Chronic kidney disease, heart failure and neprilysin inhibition. Nephrol Dial Transplant. 2020, 35:558-64. 10.1093\/ndt\/gfz058","journal-title":"Nephrol Dial Transplant"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-306775","article-title":"The neprilysin pathway in heart failure: a review and guide on the use of sacubitril\/valsartan","volume":"102","author":"Jhund PS","year":"2016","unstructured":"Jhund PS, McMurray JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril\/valsartan. Heart. 2016, 102:1342-7. 10.1136\/heartjnl-2014-306775","journal-title":"Heart"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000093","article-title":"Sacubitril\/valsartan: a novel cardiovascular combination agent","volume":"24","author":"Sible AM","year":"2016","unstructured":"Sible AM, Nawarskas JJ, Alajajian D, Anderson JR. Sacubitril\/valsartan: a novel cardiovascular combination agent. Cardiol Rev. 2016, 24:41-7. 10.1097\/CRD.0000000000000093","journal-title":"Cardiol Rev"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/s0009-8981(98)00062-x","article-title":"Association between atrial natriuretic peptide and cyclic GMP in hypertension and in chronic renal failure","volume":"275","author":"Sagnella GA","year":"1998","unstructured":"Sagnella GA, Saggar-Malik AK, Buckley MG, Markandu ND, Eastwood JB, MacGregor GA. Association between atrial natriuretic peptide and cyclic GMP in hypertension and in chronic renal failure. Clin Chim Acta. 1998, 275:9-18. 10.1016\/s0009-8981(98)00062-x","journal-title":"Clin Chim Acta"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1152\/advan.00177.2016","article-title":"The renal and cardiovascular effects of natriuretic peptides","volume":"41","author":"Wong PC","year":"2017","unstructured":"Wong PC, Guo J, Zhang A. The renal and cardiovascular effects of natriuretic peptides. Adv Physiol Educ. 2017, 41:179-85. 10.1152\/advan.00177.2016","journal-title":"Adv Physiol Educ"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110596","article-title":"The role of sacubitril\/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: from clinical trials to real-world settings","volume":"130","author":"Mazza A","year":"2020","unstructured":"Mazza A, Townsend DM, Torin G, et al.. The role of sacubitril\/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: from clinical trials to real-world settings. Biomed Pharmacother. 2020, 130:110596. 10.1016\/j.biopha.2020.110596","journal-title":"Biomed Pharmacother"},{"key":"ref42","article-title":"Sacubitril-Valsartan","author":"Nicolas D","year":"2016","unstructured":"Nicolas D, Kerndt CC, Reed M. Sacubitril-Valsartan. StatPearls Publishing, Treasure Island, FL; 2016."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.06.011","article-title":"Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization","volume":"7","author":"Bhagat AA","year":"2019","unstructured":"Bhagat AA, Greene SJ, Vaduganathan M, Fonarow GC, Butler J. Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. JACC Heart Fail. 2019, 7:1-12. 10.1016\/j.jchf.2018.06.011","journal-title":"JACC Heart Fail"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14422","article-title":"Effects of sacubitril\/valsartan on resistant hypertension and myocardial work in hemodialysis patients","volume":"24","author":"Wang B","year":"2022","unstructured":"Wang B, Wang GH, Ding XX, Tang HX, Zheng J, Liu BC, Zhang XL. Effects of sacubitril\/valsartan on resistant hypertension and myocardial work in hemodialysis patients. J Clin Hypertens (Greenwich). 2022, 24:300-8. 10.1111\/jch.14422","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-877","article-title":"Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI)","volume":"10","author":"Chen C","year":"2021","unstructured":"Chen C, Wu X, Li Y, Peng Y. Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI). Ann Palliat Med. 2021, 10:5455-61. 10.21037\/apm-21-877","journal-title":"Ann Palliat Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13137","article-title":"Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling","volume":"8","author":"Docherty KF","year":"2021","unstructured":"Docherty KF, Campbell RT, Brooksbank KJ, et al.. Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Fail. 2021, 8:129-38. 10.1002\/ehf2.13137","journal-title":"ESC Heart Fail"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.12.037","article-title":"Comparison of the efficacy and safety of sacubitril\/valsartan versus ramipril in patients with st-segment elevation myocardial infarction","volume":"143","author":"Rezq A","year":"2021","unstructured":"Rezq A, Saad M, El Nozahi M. Comparison of the efficacy and safety of sacubitril\/valsartan versus ramipril in patients with st-segment elevation myocardial infarction. Am J Cardiol. 2021, 143:7-13. 10.1016\/j.amjcard.2020.12.037","journal-title":"Am J Cardiol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028942","article-title":"Sex differences in clinical characteristics and outcomes after myocardial infarction with low ejection fraction: insights from PARADISE-MI","volume":"12","author":"Wang X","year":"2023","unstructured":"Wang X, Jering KS, Cikes M, et al.. Sex differences in clinical characteristics and outcomes after myocardial infarction with low ejection fraction: insights from PARADISE-MI. J Am Heart Assoc. 2023, 12:e028942. 10.1161\/JAHA.122.028942","journal-title":"J Am Heart Assoc"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0000000000000955","article-title":"Benefits of early administration of sacubitril\/valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention","volume":"32","author":"Zhang Y","year":"2021","unstructured":"Zhang Y, Wu Y, Zhang K, Ke Z, Hu P, Jin D. Benefits of early administration of sacubitril\/valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention. Coron Artery Dis. 2021, 32:427-31. 10.1097\/MCA.0000000000000955","journal-title":"Coron Artery Dis"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer MA","year":"2021","unstructured":"Pfeffer MA, Claggett B, Lewis EF, et al.. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. N Engl J Med. 2021, 385:1845-55. 10.1056\/NEJMoa2104508","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1159\/000527357","article-title":"The value of sacubitril\/valsartan in acute anterior wall ST-segment elevation myocardial infarction before emergency percutaneous coronary intervention","volume":"147","author":"Lin G","year":"2022","unstructured":"Lin G, Chen W, Wu M, Dai C, Xu K. The value of sacubitril\/valsartan in acute anterior wall ST-segment elevation myocardial infarction before emergency percutaneous coronary intervention. Cardiology. 2022, 147:479-85. 10.1159\/000527357","journal-title":"Cardiology"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.059210","article-title":"Impact of sacubitril\/valsartan compared with ramipril on cardiac structure and function after acute myocardial infarction: the PARADISE-MI echocardiographic substudy","volume":"146","author":"Shah AM","year":"2022","unstructured":"Shah AM, Claggett B, Prasad N, et al.. Impact of sacubitril\/valsartan compared with ramipril on cardiac structure and function after acute myocardial infarction: the PARADISE-MI echocardiographic substudy. Circulation. 2022, 146:1067-81. 10.1161\/CIRCULATIONAHA.122.059210","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/206480-the-safety-and-efficacy-of-the-early-use-of-sacubitrilvalsartan-after-acute-myocardial-infarction-a-meta-analysis-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:17:27Z","timestamp":1707509847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/206480-the-safety-and-efficacy-of-the-early-use-of-sacubitrilvalsartan-after-acute-myocardial-infarction-a-meta-analysis-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":52,"URL":"https:\/\/doi.org\/10.7759\/cureus.53784","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,7]]}}}